GUARD THERAPEUTICS INTERNATIONAL AB

Insiders Guard Therapeutics International AB

Equities

GUARD

SE0021181559

Market Closed - Nasdaq Stockholm Other stock markets 11:18:20 2024-04-29 am EDT			5-day change	1st Jan Change
29.6 ^SEK	-0.67%		+2.78%	-17.32%

Apr. 15	Guard Therapeutics Receives First Regulatory Approval for the Phase 2b Study POINTER	CI
Feb. 21	Guard Therapeutics International AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Insiders

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Guard Therapeutics International AB Appoints Nomination Committee for 2024	Dec. 07	CI
Guard Therapeutics presents the Nomination Committee for 2023	22-12-20	AQ
Guard Therapeutics International AB Announces Nomination Committee Appointments	22-12-20	CI
Guard Therapeutics International AB Appoints Torbjörn Larsson as Head of CMC (Chemistry, Manufacturing and Controls), Effective 1 May 2022	22-04-26	CI
Guard Therapeutics Appoints Michael Reusch as Chief Medical Officer, Effective January 1, 2022	21-12-15	CI
Guard Therapeutics appoints Sara Thuresson as Head of Clinical Operations	21-02-15	CI
Guard Therapeutics Appoints Ann-Kristin Myde as Head of Global Project Management, Effective 1 April 2021	20-12-28	CI
Guard Therapeutics Appoints Peter Gilmour as Head of Preclinical Science, Effective 1 August 2020	20-07-06	CI
A1M Pharma AB will Change its Name to Guard Therapeutics International AB	19-10-29	CI
A1M Pharma Appoints Tobias Larsson Agervald as Chief Medical Officer	18-08-14	CI
A1M Pharma Appoints Martin Austin as Business Development Director	15-09-25	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Like the pros, access all the transcripts and spot the best opportunities before anyone else.

Unlock them now!

fermer